Sep 08, 2020 7:00 am EDT Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors
Sep 01, 2020 7:00 am EDT Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive Multiple Sclerosis at MSVirtual2020
Aug 05, 2020 4:01 pm EDT Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress
Jul 29, 2020 4:01 pm EDT Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
Jun 24, 2020 4:34 pm EDT Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jun 17, 2020 8:47 am EDT Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis
Jun 05, 2020 4:15 pm EDT Atara Biotherapeutics Announces its 2020 Annual Meeting of Stockholders Will Be Held on June 16, 2020 in Virtual Format
May 26, 2020 4:05 pm EDT Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants